A Comprehensive in silico study for the Identification of Therapeutic target against Peripheral Neuropathic Pain in human
Background: VGF (non-acronymic) is a neuropeptide precursor or neuro-protein or neurosecretory protein which plays vital roles in the regulation of gastric contractility, mood regulation, and peripheral neuropathic pain and possibly, cancer. Objective: VGF may be a potential target as it has a unique contribution to the development of neuropathic pain which is a target for Oxymatrine (OMTR). Method: Based on this, we have endeavored to discover VGF inhibitors from the ChEMBL database of Oxymatrine (OMTR) analogues by employing homology modelling, molecular docking and pharmacophore analysis. Result: Our in silico investigation reveals that 13-Methoxymatrine has desired characteristics for becoming a future formulation. Conclusion: To confirm the efficacy of this compound, essential animal and clinical trials are needed to be performed. We believe that our present study will help to find an efficient and effective therapy for treating neuropathic pain in human which is modulated by VGF.